- Health
- SEE MORE
- classical
- general
- talk
- News
- Family
- Bürgerfunk
- pop
- Islam
- soul
- jazz
- Comedy
- humor
- wissenschaft
- opera
- baroque
- gesellschaft
- theater
- Local
- alternative
- electro
- rock
- rap
- lifestyle
- Music
- como
- RNE
- ballads
- greek
- Buddhism
- deportes
- christian
- Technology
- piano
- djs
- Dance
- dutch
- flamenco
- social
- hope
- christian rock
- academia
- afrique
- Business
- musique
- ελληνική-μουσική
- religion
- World radio
- Zarzuela
- travel
- World
- NFL
- media
- Art
- public
- Sports
- Gospel
- st.
- baptist
- Leisure
- Kids & Family
- musical
- club
- Culture
- Health & Fitness
- True Crime
- Fiction
- children
- Society & Culture
- TV & Film
- gold
- kunst
- música
- gay
- Natural
- a
- francais
- bach
- economics
- kultur
- evangelical
- tech
- Opinion
- Government
- gaming
- College
- technik
- History
- Jesus
- radio
- movies
- services
- Church
- podcast
- Education
- international
- Transportation
- Other
- kids
- podcasts
- philadelphia
- Noticias
- love
- sport
- Salud
- film
- and
- 4chan
- Disco
- Stories
- fashion
- Arts
- interviews
- hardstyle
- entertainment
- humour
- medieval
- literature
- alma
- Cultura
- video
- TV
- Science
- en
Developing Potent Oral Kinase Inhibitor to Treat Recurrent Difficult to Treat Brain Cancer with Scott Megaffin Adastra Pharmaceuticals
Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas. He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well.
#Glioblastoma #braintumor #drugdevelopment #braincancer #NCI
